Objectives Intrauterine contracepives (IUCs) are highly effective and safe for use in all women, including those who are nulliparous. However, many myths and barriers prevent more widespread utilisation. The objective of this article was to explore the health care provider (HCP), health system and user issues that prevent more widespread use of IUCs, particularly among nulliparous women, and to present the evidence that supports achieving greater utilisation of these devices. Methods MEDLINE, PubMed and Embase were used to identify studies reporting attitudes and beliefs around IUCs, and clinical studies providing evidence of their risks and bene fi ts. Results HCP, health system and user factors limiting use of IUCs were identifi ed. The most widely explored barriers in published studies are those at the HCP level. User barriers are less well documented and health system barriers are mostly assessed through indirect evidence. Many, but not all, of the barriers can be reduced through greater understanding of the evidence. Conclusions Efforts need to be made to disseminate the evidence, which shows that few contraindications exist to IUC use. Addressing HCP lack of knowledge, training and confidence with IUC insertions, particularly in nulliparous women, could make a substantial positive impact on IUC utilisation.
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Despite improved access to contraceptive methods over the last 30 years, ' failure ' of methods requiring daily decisions still contributes to between half and two-thirds of unplanned pregnancies in the USA and Europe 1,2 . Interventions to improve compliance with pills using different counselling strategies and/or instituting immediate-start protocols have not consistently improved contraceptive use patterns or continuation rates, or reduced unintended pregnancies 3, 4 . As such, international experts believe that improving access to long-acting reversible contraceptives (LARCs) -including implants, injectables and intrauterine contraceptives (IUCs) -will be an effective strategy to reduce unintended pregnancies 5 . These unintended conceptions impact on the economic, social, psychological and physical aspects of women ' s lives, and have repercussions on subsequent maternal and child health 6 . For these reasons, expanding access to LARCs was declared a national public health priority in the USA in 2009 7 . LARCs, including intrauterine contraceptives (the copper devices [Cu-IUDs] and the levonorgestrel releasing-intrauterine system [LNG-IUS] ), are among the most cost-effective of all contraceptive methods 8 -10 . Despite these advantages, IUCs are little used in many countries 11 particularly among young women, who are most susceptible to unplanned pregnancies 12 . Published data from 2002 suggested only 1.2% of contraceptors in Australia have opted for an IUC; however, with increased uptake of the LNG-IUS since then, the percentage is likely to be much higher in 2012 13 . In the USA and UK, 5 and 10% of women (aged 15 -49 years who are married or in union), respectively, select an intrauterine method 11 . In contrast, 23% of such women in Norway, 26% in Finland and only 5% in Germany choose an IUC as their family planning (FP) method 11 .
Diverse issues lead to low utilisation of IUCs; they include health care provider (HCP), health system and user factors. It is likely that reluctance to use these methods may result from a lack of understanding of recent evidence 14 . The 1970s class action lawsuits against the manufacturers of the Dalkon Shield in the USA linked that particular IUD to pelvic infection, infertility, and even death from sepsis 15 . There is good evidence that modern devices do not carry the same risks, but unbalanced information about the benefi ts and risks of IUDs persist and result in reluctance among HCPs to recommend an IUC, and reluctance among women to take up these methods 16 . The misunderstandings about the risk of IUC-related infection may impact utilisation in nulliparous women, despite the fact that international guidelines support their use in this group 17 .
This paper aims to present a review of published evidence of the factors that impact negatively on IUC use. We were particularly interested in the myths and barriers surrounding use in nulliparous women, although any of the obstacles to more prevalent use apply to all women, regardless of parity.
M E T H O D S
We undertook a literature search of articles published in English between 1990 and 2012 through Embase, PubMed and MEDLINE using the following MeSH headings: intrauterine devices; intrauterine devices, copper; intrauterine devices, medicated; attitudes; satisfaction; clinician knowledge; effi cacy; and costeffectiveness. We reviewed primary studies of any study design that looked at provider and user knowledge and attitudes towards IUCs. Further articles examining clinical outcomes of IUC utilisation were reviewed, focussing on cohort studies and randomised controlled trials when possible. Reference lists of all articles were checked to identify further relevant studies. Due to resource constraints, searching of the grey literature and hand searching were not carried out. We specifi cally aimed to explore the health system, HCP and user barriers that impact on uptake of IUCs, and to explore some of the ways in which these can be addressed.
H E A L T H C A R E P R O V I D E R B A R R I E R S : M Y T H S A N D E V I D E N C E

Misperceptions regarding the risk of PID, infertility and ectopic pregnancy
The Dalkon Shield, which was responsible for several cases of severe and potentially fatal pelvic sepsis, has now been off the market for more than 30 years, but it still tarnishes the reputation of modern intrauterine contraceptives in certain countries 18 . Many HCPs believe that having an IUC in situ is associated with 342 The European Journal of Contraception and Reproductive Health Care an ongoing risk of pelvic infl ammatory disease (PID) and resultant infertility [18] [19] [20] [21] [22] . This misperception is a particular barrier to IUC use in nulliparous women, especially if they are single or have several sexual partners 19, 20, 23 . This is despite the fact that there is strong evidence that Chlamydia infection causes PID and infertility, not the presence of an IUC 20, 24, 25 . Some HCPs may feel inclined to use antibiotics to prevent infection at the time of intrauterine contraceptive insertion. However, two large, randomised, placebo-controlled studies conducted in the US 26 and Kenya 27 showed no signifi cant benefi t of prophylactic antibiotics in reducing the risk of PID following IUC insertion. In the US-based study 26 1985 women in California who were at low risk of STIs according to self-reported medical history were randomised to azithromycin 500 mg orally or placebo approximately one hour prior to insertion of an IUC. Of 918 women in the antibiotic group and 915 women in the placebo group who had a device inserted and were followed for 90 days, only one woman in each group developed salpingitis 26 . In the African study 27 , 1813 women were randomised to receive doxycycline 200 mg orally or placebo at the time of IUC insertion; 1.3% and 1.9% of women developed PID in the antibiotic and placebo groups, respectively ( p ϭ 0.17), showing no signifi cant benefi t associated with antibiotic prophylaxis 27 . In addition, a later systematic review of the literature concluded that doxycycline 200 mg or azithromycin 500 mg given orally before IUC insertion ' confers little benefi t ' 28 .
Other studies have described the risk of placing an intrauterine contraceptive through a cervix that is already infected with Chlamydia. These trials showed that few to no women developed PID after insertion with positive Chlamydia testing (none out of fi ve women 29 , none out of nine women 30 , none out of 13 women 31 , two out of 19 women 32 ). Of course, it is impossible to know how many of those women with asymptomatic chlamydial infections would have gone on to develop PID in the absence of IUC insertion.
In a study of 1895 women in Mexico, use of Cu-IUDs was not associated with subsequent infertility; however, evidence of previous Chlamydia infection was shown to be a risk factor 25 . There is even some evidence that use of the LNG-IUS might provide some protection against PID. In one randomised trial comparing the LNG-IUS with Cu-IUDs in more than 2500 women over a follow-up period of three years, the rate of PID was signifi cantly lower in LNG-IUS users, and the rate of PID in Cu-IUD users was similar to the background risk of PID in non-users, suggesting that the LNG-IUS might protect against PID 20, 33 .
The relationship between ectopic pregnancy and use of an IUC is also poorly understood. HCPs have been found both to overestimate the risk of ectopic pregnancy and to consider a past history of ectopic pregnancy to be a contraindication to future use of an IUC 34 . It is true that a woman who becomes pregnant with an IUC in situ has a 10.6-fold increased chance that the pregnancy will be ectopic compared to a woman who has become pregnant under other circumstances 35, 36 ; nevertheless, what is less appreciated is that a woman ' s absolute risk is extremely low compared to using no contraception 37 . A history of ectopic pregnancy is listed as category 1 (no restriction) for use of an IUC in the WHO Medical Eligibility Criteria for contraceptive use 17 .
Misperceptions about the diffi culty and risks of insertion of IUCs
HCPs have reported reluctance to insert an IUC into women who have not given birth to a child, because of the perceived technical challenges 20, 38 . Although studies do suggest an increased rate of insertion problems in nulliparous women 39 , the vast majority of women will have an IUC inserted with ease regardless of parity 40 . According to physicians in New Zealand inserting the LNG-IUS, the relative risk of a diffi cult insertion in women who were nulliparous compared to parous women was 1.6 (95% confi dence interval [CI]: 1.0 -2.6) 39 . However, the reporting of diffi culty was also signifi cantly associated with HCP experience 39 .
Evidence for insertion success in nulliparous women comes from several case series. In a Swedish noninterventional study of LNG-IUS insertions in 224 nulliparous women, only six insertions were unsuccessful and more than 70% were regarded as ' easy ' by the inserting clinician 41 . In another study comparing the LNG-IUS with oral contraceptives in young nulliparous women in Finland and Sweden, HCPs reported that insertion of the LNG-IUS was ' easy ' in 85% of cases (80/94 insertions) and only two of the 94 attempted insertions failed 42 . In a retrospective study conducted in Brazil comparing LNG-IUS Few data directly comparing insertion-related pain in nulliparous women versus parous women exist, but the evidence suggests that it is likely to be greater in nulliparous women. A higher pain score for the insertion of the CuT380A in nulliparous versus parous women (mean of 2.7 cm vs. 1.9 cm on a 10 cm visual analogue scale) has been reported 43 , although neither score was particularly high. In the Swedish study of LNG-IUS insertions in nulliparous women, moderate to severe pain was experienced by almost 90% of all participants at the time of insertion 41 . Misoprostol (a prostaglandin analogue and cervical ripening agent) appears to aid insertion in nulliparous women from the HCP ' s perspective 44 , but has no impact on discomfort during insertion from the woman ' s perspective 44, 45 .
Another concern is the risk of uterine perforation, which HCPs perceive as being greater in nulliparous women 20 . Although data about perforation are likely to underestimate the true incidence of perforation because of insuffi cient length of follow-up, loss to follow-up and unrecognised cases, there is some evidence that the risk is indeed higher in women who have not had a child, or have had a termination of pregnancy, but is probably greatest for women in the post-partum period 46 .
In a European study of IUC insertions in 8343 women, the rate of uterine perforation was 2.2 per 1000 women 46 . The authors found that higher parity lessened the risk (odds ratio [OR] : 0.04, CI: 0.01 -0.1) whereas a greater number of abortions increased the risk (OR: 2.1, CI: 1.2 -3.6). However, the greatest risk was observed in women who were 0 -3 months postpartum (OR: 11.7, CI: 2.8 -49.2) and those 4 -6 months post-partum (OR: 13.2, CI: 2.8 -62) 46 . This fi nding was supported by an earlier study which showed that 90% of women with IUC perforations had the device inserted within 12 months of a full-term pregnancy and 62% had been within 12 weeks, suggesting the softer post-pregnancy uterine wall was predisposed to perforation 47 .
The rates of perforation reported for all women (regardless of parity) amounted to 1.6 per 1000 insertions in a prospective study of 17,469 Multiload Ò Cu375 insertions 48 . The authors noted that most perforations were not recognised at the time of insertion and some of the cases were not identifi ed until years afterwards or possibly remained undiagnosed. Therefore, it is likely that all the published studies might underestimate the true risk.
Recently a number of case series have examined the risk of perforation associated with insertions in nulliparae. In a pilot study of Cu-IUD/LNG-IUS insertions in such women, none of 113 successful insertions resulted in uterine perforation 49 , and in a study of LNG-IUS (Mirena Ò ) insertions in Sweden, none of 218 successful insertions performed in nulliparous women resulted in perforation 41 , although scheduled follow-up in each of these studies was only 12 months.
When inserted, some HCPs believe that IUCs in nulliparous women may have a higher risk of expulsion. Again, the data do not support this belief. In a Dutch study evaluating complications of IUCs according to parity, the expulsion rate for Cu-IUDs was 0-2.8% per year among 142 nulliparae versus 0-1.4% per year among 443 parous women; this difference was not statistically signifi cant 50 . In a Brazilian study comparing use of the LNG-IUS in nulliparous and parous women, the expulsion rate within the fi rst year after insertion was similar ( ∼ 4%) in both groups 40 . Furthermore, in the US-based Contraceptive CHOICE Project, the one-year Cu-IUD/LNG-IUS expulsion rate among 437 nulliparae was 2.5%, compared with 5.6% among parous women 51 .
Misperceptions about the mechanism of action
Concern over the mechanism of action of copper IUDs has also dissuaded HCPs from recommending or inserting, and women from using IUCs. For many years it was thought that IUDs exerted their effect by preventing implantation of a fertilised egg and for a number of those who believed that life begins at conception, IUC use was considered morally unacceptable 19, 52, 53 .
Various studies have confi rmed that the main mechanism of action is in effect prior to fertilisation. IUCs create a sterile infl ammatory response that immobilises sperm, and women with one of these devices in place have considerably fewer fertilised ova in their Fallopian tubes than women not using contraception 52, 54, 55 . Wilcox and colleagues 56,57 utilised a highly sensitive immunoradiometric assay for hCG in user and nonusers of IUDs in order to detect the earliest possible 344 The European Journal of Contraception and Reproductive Health Care evidence of an embryo. In over 100 cycles in IUD users, they detected only one case of transient hCG elevation while their controls had four transient rises in 89 cycles. Their conclusion was, ' the IUD interferes with the reproductive process before the embryo produces enough hCG to be detected in the maternal body fl uids ' . In a comprehensive review from 2007 which cited the previous papers and several others, Ortiz and Croxatto stated, ' The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence ' 58 . The LNG-IUS, in addition, causes thickening of the cervical mucus, which impedes transport of sperm through the cervix 59 (Table 1) 52, 54, 55, 60, 61 .
H E A L T H S Y S T E M B A R R I E R S
Pharmaceutical guidelines
In many countries, attitudes regarding candidates for IUC use are reinforced by guidelines, package inserts or product labelling that recommend IUCs for multiparous women 62 . In 2005, the US Food and Drug Administration (FDA) approved the package insert for the CuT380A IUD in which the requirement for the device to be used in women with one or more children had been removed. However, the LNG-IUS still has not received specifi c FDA approval for use in nulliparous women 8 , making its use in this group ' off label ' . Given the medico-legal environment in the USA, this may prohibit HCPs from inserting a LNG-IUS in nulliparous women. Furthermore, many providers working for large organisations (health departments, Planned Parenthood) often have to practise within regulations related to package inserts and, therefore, are not allowed to place a LNG-IUS in nulliparous women even if they believe it is safe. In a survey about use of IUCs among American gynaecologists, 16% felt that inserting IUDs would lead to lawsuits against them 19 .
Lack of understanding of the value/costeffectiveness of IUCs
Because the up-front costs of intrauterine contraception are high in some countries, it may be perceived as being an expensive option. However, once placed an IUC is effective for several years and over time becomes cost-effective 9, 10, 63 . The Cu-IUD, the LNG-IUS and vasectomy were actually the three most cost-effective methods of contraception over fi ve years of use in a US-based analysis 10 . Although the health care system as 
Factors affecting the number of trained providers
Some HCPs who are competent in IUC insertion may be hesitant to have more providers gain those skills, for fear they will lose an important source of revenue. In other health care systems, referral systems may make it more benefi cial for HCPs to send women elsewhere for IUC placement than to spend the time and money to provide this care themselves. A survey in the US analysing IUC insertion found that of the HCPs not providing IUCs, 47% cited lack of reimbursement as a reason for not performing insertions 23 . Both scenarios lead to shortages of skilled providers to insert IUCs.
U S E R B A R R I E R S : M Y T H S A N D E V I D E N C E
Many of the HCP barriers and health system barriers overlap or become user barriers. For example, if a woman obtains most of her information about contraception from a HCP who is not up to date with evidence-based practice on intrauterine methods, she is likely to be subjected to common myths that may negatively impact her perception of the devices. Similarly, if her insurance does not pay for contraceptive benefi ts, paying for the device may be a diffi cult barrier to overcome. In this section we will discuss the issues that are unique to the user.
Women ' s lack of awareness and understanding of IUC
In one study of 252 women aged 14 -27 presenting to a FP clinic, 55% had not heard of IUCs 67 , and those who were parous were 4.4 times more likely to be interested in this modality of birth control compared with nulliparous women. If a woman had been educated about IUCs by their HCP, she was 2.7 times more likely to be interested in using one of these 67 . In another study of 144 women aged 14 -24 who were given a knowledge survey prior to a three-minute educational intervention 68 , 60% had not heard of IUCs before the teaching. Of those who had heard of the method, only 37.5% had a positive attitude before the intervention. After the education, 53.5% had a positive attitude about IUCs and the participants particularly liked the fact that the method was long acting and very private. In a study in which 40 women were asked more detailed questions about intrauterine contraception, Rubin and Winrob 69 determined that women had conceptual concerns and fears about letting a foreign body be placed inside their womb. Their respondents also believed that an IUC was to be used only when other FP methods had failed. Finally, the women in this study reported a lack of discussion and information about IUCs from their HCP, in the media or from informal networks 69 . In an Australian study, women were surveyed when they presented to FP clinics for IUC insertion. There were 318 completed questionnaires among 334 women who attended over a three-month period; 16% of respondents (51/318) had not found it easy to obtain IUC-related information, and almost a fi fth (58/318) had been told it was not a suitable method for them by either a HCP or a friend or family member (or both), despite these women meeting appropriate medical eligibility criteria at the FP clinic 70 .
Fear of IUC
In a large study undertaken to determine women ' s knowledge of intrauterine contraception, 12,500 questionnaires were randomly sent to homes in St. Louis, Missouri, USA in 2008 71 and the results from 1665 responses were analysed. Knowledge of the expected side effects and safety was limited. Although 49% considered that method as safe, those who felt it was not (8%) or were unsure (43%) thought that it increased the risk of ectopic pregnancy, cancer or sexually transmitted infections. Some women may avoid IUCs for fear that the actual insertion will be too painful 43, 45 . Although a Cochrane Library review has suggested that, to date, no effective intervention has been proven to decrease this insertional pain 45 , many studies show high rates of acceptance 41, 42, 49, 72 . It is up to the provider to allay those fears with proper counselling and accurate information.
Discontinuations due to bleeding pattern changes
A change in bleeding pattern is a common reason that women discontinue their contraceptive method. It is well established that copper devices may increase the quantity of blood being lost as well as the length and pain associated with menses, whereas the LNG-IUS typically decreases menstrual blood fl ow and may even lead to amenorrhoea in a signifi cant number of users. In early comparative studies, Nilsson et al . 73 reported higher discontinuation rates for ' bleeding problems ' in users of two different LNG-IUSs (LNG-IUS A, release rate 20 μ g/day and LNG-IUS B, release rate 30 μ g/day) compared with women using a copper device (Nova T); conversely, Andersson et al . 74 reported higher discontinuation rates for ' bleeding problems ' in copper device (Nova T) users compared with those using an LNG-IUS (release rate 20 μ g/ day). In Nilsson ' s study, 11% of women using LNGIUSs were amenorrhoeic at the end of the fi rst year of use; the discontinuation rates due to amenorrhoea were 2.6% and 4.1% for the lower (20 μ g/day) and higher (30 μ g/day) dose LNG-IUSs, respectively 73 . In Andersson ' s study, 6% of LNG-IUS users discontinued because of amenorrhoea 74 . In a more recent study of 136 adolescents, 7.4% had the device removed within the fi rst year as a result of bleeding-related complaints, with no difference in rate by IUC type 75 . Women also need to be educated about the bleeding pattern changes to be expected with an IUC, so that they are able to select the method that is best for them and hopefully continue with it as long as pregnancy is not desired. In the Contraceptive CHOICE Project, where education covered expected bleeding pattern, continuation at 12 months was 88% for the LNG-IUS and 84% for copper devices 72 .
Cost of the IUC as a barrier
Cost as a barrier to IUC use has been poorly explored. An impression of the impact of the up-front expense on use can be drawn from the differing experiences in Australia and New Zealand. In New Zealand, the copper IUDs are subsidised and women pay 19 Euros (US $ 25), whereas the LNG-IUS costs approximately 228 Euros (US $ 300). The reverse is true in Australia: the LNG-IUS is subsidised and the copper IUDs are not. Although cost is probably not the only reason for increased acceptability and utilisation of the LNG-IUS in Australia, it is likely to be a contributing factor.
The Contraceptive CHOICE Project sought to remove fi nancial barriers while increasing women ' s knowledge of the safety and effi cacy of LARCs. Among the fi rst 2500 women enrolled in this St. Louis, Missouri study, 67% chose a LARC and of those, 56% decided on an IUC 76 . In comparison, the most recent National Survey of Family Growth reported that less than 6% of contraceptors in the USA use an IUC 76 . Overall, these data suggest that if all barriers were removed, IUC use would greatly increase in the USA.
O V E R C O M I N G T H E O B S T A C L E S
Addressing HCP misperceptions
Contraception must be an integral part of medical education, prior to the point of specialisation. This allows HCPs in all specialties to provide women with accurate information to meet their reproductive needs, even if they will not be the actual provider of services. Women ' s health practitioners with various levels of training from physician, to nurse, to midwife, must be additionally trained to insert IUCs. Those who have completed their training without these skills should have ample opportunity, in both didactic and hands-on training, to learn IUC placement.
Addressing the health system barriers
There must be incentives for experts to train others without fear of losing a revenue stream, and for others The Contraceptive CHOICE Project also demonstrated how patient education can impact positively on IUC uptake 72 . Clearly both uptake and continuation of intrauterine contraception are infl uenced by education.
F U T U R E R E S E A R C H
Future areas for research need to address the gaps in the evidence base. More information about both short-and long-term use in nulliparous women, including young women ' s knowledge of and attitudes towards IUCs, may persuade HCPs towards recommending them. More information is needed about the HCP and system barriers, including the impact of training, time constraints and remuneration. The impact of the up-front cost of IUCs on user uptake also needs to be further explored.
C O N C L U S I O N This review has identifi ed a number of barriers to IUC use including HCP, health system and user barriers; however, the beliefs of HCPs have perhaps the most profound effect on uptake of these methods. There is suffi cient evidence to support the use of IUCs in nulliparous women in terms of safety (low insertion and expulsion risks as well as minimal risk of infection or ectopic pregnancy) and both shortand long-term satisfaction/continuation. The challenge is to ensure that HCPs understand the evidence and do not discount IUCs for nulliparous women but rather offer them, along with other contraceptive options, as a suitable method to be considered.
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